Comparison of the Effect Site Concentration of Remifentanil for Preventing Cough During Emergence Between Male and Female Patients With Thyroidectomy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Yonsei University
ClinicalTrials.gov Identifier:
NCT01614535
First received: June 3, 2012
Last updated: June 7, 2012
Last verified: June 2012

June 3, 2012
June 7, 2012
August 2011
March 2012   (final data collection date for primary outcome measure)
occurrence of cough [ Time Frame: 20 minutes after sevoflurane off ] [ Designated as safety issue: No ]

The cough was defined as a sudden contraction of the abdomen. The level of cough was assessed and recorded by the following cough grading system: Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 sec with moderate severity; Grade 3, severe, persistent cough for more than 5 sec.

The patients will be followed from Sevolurane off to being transported to PACU.

Same as current
Complete list of historical versions of study NCT01614535 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Comparison of the Effect Site Concentration of Remifentanil for Preventing Cough During Emergence Between Male and Female Patients With Thyroidectomy
Not Provided

The clinical studies demonstrate more powerful analgesic effect among female to both μ- and κ-opioid agonist (Fillingim et al. 2004). The antitussive effect of opioid is mediated predominantly by μ-, κ-opioid receptors (Kamei J. 1996). Therefore, the investigators hypothesized that there are sex differences in the antitussive responses to opioid.

It has been reported that target-controlled infusion (TCI) of remifentanil can reduce cough against endotracheal tube during emergence from general anesthesia. Some studies, reporting the EC50 and EC95 of remifentanil in effect-site TCI for preventing cough during emergence in different sex and surgeries (B. Lee et al. 2009, E.M.Choi et al. 2012), showed differences in EC50 and EC95.

The purpose of this study was to find out EC50 and EC95 of remifentanil in effect-site TCI for preventing cough during emergence in each sex and to evaluate whether there were sex differences in EC50 and EC95 of remifentanil in effect-site TCI or not.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Patients Undergoing Thyroidectomy
Drug: up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence
Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
Other Name: remifentanil Ce, Ultiva Ce
  • Experimental: Female group
    Female gender patients undergoing thyroidectomy
    Intervention: Drug: up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence
  • Active Comparator: Male group
    Male gender patients undergoing thyroidectomy
    Intervention: Drug: up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
46
March 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • aged 20-46
  • ASA classification I~II
  • patients undergoing thyroidectomy

Exclusion Criteria:

  • patient who has signs of a difficult airway
  • patient who has smoking history
  • patient who has upper respiratory infection or sore throat in the previous two weeks
  • patient who has hypertension, DM
  • female patients who were pregnant, breast-feeding or menopausal
Both
25 Years to 46 Years
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01614535
4-2011-0356
Yes
Yonsei University
Yonsei University
Not Provided
Principal Investigator: Wyun Kon Park, MD Yonsei University College of Medicine, Department of Anesthesiology and Pain Medicine
Yonsei University
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP